Published in CA Cancer J Clin on May 20, 2002
Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | NCT03829930
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2006) 1.78
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer (2006) 1.23
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer (2011) 1.17
Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin (2014) 1.15
Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol (2012) 1.10
Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc. Cancer Sci (2011) 1.10
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem (2007) 1.07
Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol (2013) 1.01
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. Diagn Pathol (2014) 1.01
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer (2009) 1.00
A review of the anticancer and immunomodulatory effects of Lycium barbarum fruit. Inflammopharmacology (2011) 1.00
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med (2014) 0.98
Does the microenvironment influence the cell types of origin for prostate cancer? Genes Dev (2013) 0.97
The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells. Biochem Biophys Res Commun (2007) 0.96
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett (2012) 0.95
Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther (2003) 0.94
Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res (2009) 0.94
An expression signature at diagnosis to estimate prostate cancer patients' overall survival. Prostate Cancer Prostatic Dis (2014) 0.93
Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? Front Oncol (2014) 0.93
Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer. Can Urol Assoc J (2015) 0.92
Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells. PLoS One (2012) 0.90
Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget (2015) 0.90
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol (2012) 0.87
Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235). Br J Cancer (2009) 0.86
Hormonal therapy for prostate cancer. Rev Urol (2006) 0.85
Cholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cells. PLoS One (2013) 0.85
Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective. Rev Urol (2003) 0.84
Castration-resistant prostate cancer: systemic therapy in 2012. Clinics (Sao Paulo) (2012) 0.84
Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res (2011) 0.84
Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells. PLoS One (2013) 0.83
Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin Pharmacol Ther (2015) 0.83
Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat (2010) 0.82
Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues. Indian J Urol (2009) 0.82
The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer. Ther Adv Urol (2015) 0.81
Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2. PLoS One (2014) 0.81
Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling. Int J Mol Sci (2013) 0.80
Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag (2014) 0.80
The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets (2013) 0.80
Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Ther Adv Urol (2015) 0.78
Identification of beta-2 as a key cell adhesion molecule in PCa cell neurotropic behavior: a novel ex vivo and biophysical approach. PLoS One (2014) 0.78
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance. Cell Signal (2016) 0.77
Integrated network model provides new insights into castration-resistant prostate cancer. Sci Rep (2015) 0.77
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. Drug Discov Today Ther Strateg (2010) 0.76
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol (2016) 0.75
Asymmetric synthesis and evaluation of a hydroxyphenylamide voltage-gated sodium channel blocker in human prostate cancer xenografts. Bioorg Med Chem (2011) 0.75
MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget (2016) 0.75
3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc Natl Acad Sci U S A (2003) 0.75
The HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells. Am J Cancer Res (2015) 0.75
Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. Prostate Cancer Prostatic Dis (2010) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest (2011) 4.43
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev (2010) 3.24
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem (2009) 2.81
Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A (2006) 2.63
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res (2010) 2.41
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36
Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res (2007) 2.31
Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol (2002) 2.31
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia (2011) 2.21
Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res (2007) 2.14
CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (2006) 2.05
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer (2007) 2.02
Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res (2003) 1.97
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev (2009) 1.93
CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia (2007) 1.91
Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology (2005) 1.85
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res (2004) 1.82
The evolving biology and treatment of prostate cancer. J Clin Invest (2007) 1.81
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther (2003) 1.77
Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem (2008) 1.74
Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst (2010) 1.74
The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia (2002) 1.72
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71
CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem (2008) 1.71
MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia (2002) 1.71
Stromal factors involved in prostate carcinoma metastasis to bone. Cancer (2003) 1.63
Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun (2013) 1.61
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res (2009) 1.61
Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res (2012) 1.58
GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia (2010) 1.56
Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate (2007) 1.56
Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Mol Cancer Res (2012) 1.55
An in vivo mouse model for human prostate cancer metastasis. Neoplasia (2008) 1.54
Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials (2009) 1.54
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia (2009) 1.49
Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia (2005) 1.48
The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin (2007) 1.46
A sequence-based survey of the complex structural organization of tumor genomes. Genome Biol (2008) 1.45
Erythropoietin couples hematopoiesis with bone formation. PLoS One (2010) 1.44
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol (2005) 1.44
A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res (2007) 1.43
Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A (2004) 1.42
Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci U S A (2009) 1.40
Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate (2008) 1.37
Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A (2013) 1.37
Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol (2006) 1.33
Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS One (2013) 1.32
Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res (2005) 1.31
Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol (2011) 1.27
An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res (2007) 1.26
Simulating the hallmarks of cancer. Artif Life (2006) 1.25
Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One (2013) 1.23
Modeling somatic evolution in tumorigenesis. PLoS Comput Biol (2006) 1.22
FYN is overexpressed in human prostate cancer. BJU Int (2008) 1.22
Dynamic process of prostate cancer metastasis to bone. J Cell Biochem (2004) 1.22
Regulation of prostate cancer progression by galectin-3. Am J Pathol (2009) 1.21
Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res (2011) 1.21
The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res (2003) 1.18
CCL2, survivin and autophagy: new links with implications in human cancer. Autophagy (2008) 1.17
Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res (2011) 1.16
Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology. Int J Oncol (2005) 1.15
Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res (2010) 1.15
Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int J Cancer (2008) 1.15
384 hanging drop arrays give excellent Z-factors and allow versatile formation of co-culture spheroids. Biotechnol Bioeng (2011) 1.15
Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells. J Physiol (2004) 1.14
Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci (2010) 1.14
CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin Exp Metastasis (2008) 1.12
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A (2013) 1.12